Shares of DexCom (DXCM) have bounced back 15% since hitting a 52-week low early last month, yet are still down 20% so far in 2016. Kevin Sayer, CEO of Dexcom (DXCM), said topline growth expectations of 20% and advances in its mobile glucose monitoring app will maintain the momentum for the rest of the year. 'Less than 20% of people with Type 1 diabetes use continuous glucose monitoring so there is a lot of room in our core market to go and a lot of patients to add,' said Sayer. 'On top of that, glucose monitoring is also applicable to people who have Type 2 diabetes and are intensive insulin users so there is a lot of room for growth in the U.S.' DexCom supplies continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes.
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.